Replimune Group Inc reports results for the quarter ended March 31 - Earnings Summary

• Replimune Group Inc NASDAQ:REPL reported a quarterly adjusted loss of 76 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -82 cents. The mean expectation of eight analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from -79 cents to -52 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Replimune Group Inc's reported EPS for the quarter was a loss of 76 cents​.

• The company reported a quarterly loss of $73.22 million.

• Replimune Group Inc shares had risen by 52.0% this quarter and gained 19.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Replimune Group Inc is $7.32, about 58.9% below its last closing price of $11.63

This summary was machine generated from LSEG data June 29 at 12:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact )